Skip to main content

Advertisement

Table 1 Comparison of study design and treatment protocols of trials on DOACs Versus VKA for treatment of acute VTE

From: Management of venous thromboembolism: an update

Trial name RE-COVER RE-COVER II EINSTEIN-DVT EINSTEIN-PE AMPLIFY Hokusai-VTE
Year of Publication [Ref] 2009 [15] 2014 [16] 2010 [17] 2012 [18] 2013 [19] 2013 [20]
Design Double-blinded Double-blinded PROBE PROBE Double-blinded Double-blinded
Number of Patients 2539 2589 3449 4832 5395 8292
Indication for Anticoagulation Acute VTE Acute VTE Acute DVT Acute PE Acute VTE Acute VTE
DOAC Treatment Protocol Dabigatran 150 mg twice daily Dabigatran 150 mg twice daily Rivaroxaban 15 mg twice daily for 3 weeks; then 20 mg once daily Rivaroxaban 15 mg twice daily for 3 weeks; then 20 mg once daily Apixaban 10 mg twice daily for days; then 5 mg twice daily Edoxaban 60 once daily; patients with CrCl 30–50 mL/min, body weight ≤60 kg, or receiving strong P-glycoprotein inhibitors: edoxaban 30 mg once daily
Non-inferiority Margin for Hazard Ratio 2.75 2.75 2.0 2.0 1.8 1.5
Need for initial Parenteral Anticoagulation Yes Yes No No No Yes
Duration of Therapy (months) 6 6 3, 6, or 12 3, 6, or 12 6 ≤12
TTR (%) 60 57 58 63 61 64
  1. DOAC direct oral anticoagulant, DVT deep vein thrombosis, PE pulmonary embolism, PROBE prospective, randomized, open-label, blinded end point, TTR time in therapeutic range for warfarin, VKA vitamin K antagonists, VTE venous thromboembolism, CrCl creatinine clearance